Seroprevalence of Jamestown Canyon virus in the Japanese general population.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
23 Oct 2020
Historique:
received: 07 07 2020
accepted: 16 10 2020
entrez: 24 10 2020
pubmed: 25 10 2020
medline: 11 11 2020
Statut: epublish

Résumé

Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, mainly among adults. JCV is widely distributed in North America and the number of JCV cases in the U.S. has increased in recent years. Therefore, the central nervous system disease caused by JCV can be considered a potentially re-emerging viral disease. However, the seroprevalence of JCV is unknown in Japan. The purpose of this study is to evaluate the seroprevalence of JCV in the Japanese population. We used an IgG enzyme-linked immunosorbent assay (IgG-ELISA) with JCV-infected cell-lysates and/or a neutralizing (NT) antibody assay. The cut-off value of IgG-ELISA was determined using IgG-ELISA to analyze serum specimens from 37 healthy Japanese donors. IgG-ELISA was validated by assessing its sensitivity and specificity, using 38 human serum samples previously tested for the presence or absence of antibodies against JCV and snowshoe hare virus (SSHV), in an in-house NT antibody assay conducted by the Public Health Agency of Canada. The seroepidemiological study was performed using IgG-ELISA and NT antibody assay to analyze 246 human serum samples from the serum bank of the National Institute of Infectious Diseases (NIID) in Japan. The cut-off value of IgG-ELISA was determined at 0.20, based on the mean (- 0.075) and standard deviation (0.092) values using Japanese donors' sera. The sensitivity and the specificity of IgG-ELISA determined using 25 JCV-positive and 4 JCV-negative serum samples were 96 and 100%, respectively. Analysis of the 246 Japanese serum samples revealed that no specimen showed a higher value than the cut-off value of IgG-ELISA, and no sample tested positive by the NT antibody assay. Our results showed that JCV is not circulating significantly in Japan. To the best of our knowledge, this is the first report to demonstrate the seroprevalence of JCV in the general population in Japan.

Sections du résumé

BACKGROUND BACKGROUND
Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, mainly among adults. JCV is widely distributed in North America and the number of JCV cases in the U.S. has increased in recent years. Therefore, the central nervous system disease caused by JCV can be considered a potentially re-emerging viral disease. However, the seroprevalence of JCV is unknown in Japan. The purpose of this study is to evaluate the seroprevalence of JCV in the Japanese population.
METHODS METHODS
We used an IgG enzyme-linked immunosorbent assay (IgG-ELISA) with JCV-infected cell-lysates and/or a neutralizing (NT) antibody assay. The cut-off value of IgG-ELISA was determined using IgG-ELISA to analyze serum specimens from 37 healthy Japanese donors. IgG-ELISA was validated by assessing its sensitivity and specificity, using 38 human serum samples previously tested for the presence or absence of antibodies against JCV and snowshoe hare virus (SSHV), in an in-house NT antibody assay conducted by the Public Health Agency of Canada. The seroepidemiological study was performed using IgG-ELISA and NT antibody assay to analyze 246 human serum samples from the serum bank of the National Institute of Infectious Diseases (NIID) in Japan.
RESULTS RESULTS
The cut-off value of IgG-ELISA was determined at 0.20, based on the mean (- 0.075) and standard deviation (0.092) values using Japanese donors' sera. The sensitivity and the specificity of IgG-ELISA determined using 25 JCV-positive and 4 JCV-negative serum samples were 96 and 100%, respectively. Analysis of the 246 Japanese serum samples revealed that no specimen showed a higher value than the cut-off value of IgG-ELISA, and no sample tested positive by the NT antibody assay.
CONCLUSIONS CONCLUSIONS
Our results showed that JCV is not circulating significantly in Japan. To the best of our knowledge, this is the first report to demonstrate the seroprevalence of JCV in the general population in Japan.

Identifiants

pubmed: 33096994
doi: 10.1186/s12879-020-05517-2
pii: 10.1186/s12879-020-05517-2
pmc: PMC7585186
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

790

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : 17fk0108108j0601
Organisme : Japan Agency for Medical Research and Development
ID : 18fk0108035j0602
Organisme : Japan Agency for Medical Research and Development
ID : 19fk0108035j0603

Références

Viruses. 2019 Aug 29;11(9):
pubmed: 31470541
J Neurovirol. 2016 Jun;22(3):257-60
pubmed: 26903031
Emerg Infect Dis. 2009 Feb;15(2):306-9
pubmed: 19193280
J Wildl Dis. 1987 Jan;23(1):23-33
pubmed: 3820426
J Clin Lab Anal. 1993;7(4):230-7
pubmed: 8395596
Arch Virol. 2019 Jul;164(7):1949-1965
pubmed: 31065850
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1137-1142
pubmed: 30335737
Am J Trop Med Hyg. 1980 Nov;29(6):1420-7
pubmed: 7446829
Am J Trop Med Hyg. 2015 Aug;93(2):384-9
pubmed: 26033022
J Clin Microbiol. 2001 Jan;39(1):1-7
pubmed: 11136739
J Infect Chemother. 2019 Nov;25(11):917-919
pubmed: 31186196
Am J Trop Med Hyg. 2019 Feb;100(2):445-451
pubmed: 30526745
Emerg Infect Dis. 2019 Apr;25(4):728-738
pubmed: 30882310
Vector Borne Zoonotic Dis. 2008 Apr;8(2):175-88
pubmed: 18386967
Can J Infect Dis Med Microbiol. 2013 Summer;24(2):79-84
pubmed: 24421806
Virol J. 2011 Mar 24;8:136
pubmed: 21435230
MMWR Morb Mortal Wkly Rep. 2019 Aug 09;68(31):673-678
pubmed: 31393865
Can Commun Dis Rep. 2015 Jun 04;41(6):117-123
pubmed: 29769943
Emerg Infect Dis. 2018 Jan;24(1):118-121
pubmed: 29260667
PLoS Negl Trop Dis. 2016 Apr 05;10(4):e0004595
pubmed: 27045364
J Gen Virol. 1979 Feb;42(2):357-62
pubmed: 84857
Emerg Infect Dis. 2015 Mar;21(3):517-20
pubmed: 25695200
Prog Clin Biol Res. 1983;123:1-16
pubmed: 6346334
Clin Vaccine Immunol. 2007 Sep;14(9):1182-9
pubmed: 17634509
Am J Trop Med Hyg. 2015 Feb;92(2):377-93
pubmed: 25487728

Auteurs

Hirofumi Kato (H)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Masaaki Satoh (M)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Madoka Kawahara (M)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Satoshi Kitaura (S)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Tomoki Yoshikawa (T)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Shuetsu Fukushi (S)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Kristina Dimitrova (K)

Zoonotic Diseases and Special Pathogens Division, Public Health Agency of Canada, 1015 Arlington Street Winnipeg, Winnipeg, Manitoba, R3E 3R2, Canada.

Heidi Wood (H)

Zoonotic Diseases and Special Pathogens Division, Public Health Agency of Canada, 1015 Arlington Street Winnipeg, Winnipeg, Manitoba, R3E 3R2, Canada.

Masayuki Saijo (M)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan.

Mutsuyo Takayama-Ito (M)

Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan. mutsuito@niid.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH